FDA has granted an investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy Regenerative Medicine Advanced Therapy designation for treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.
Last week’s issue of The Cancer Letter included an obituary that the entire staff at The Cancer Letter had been dreading for years: Abdallah Abou Zahr, an oncologist at Roger Maris Cancer Center in Fargo, ND, died Jan. 23 of a liposarcoma after a five-year battle with the disease.
